Victoria in 1894, was educated at Caulfield Grammar School and the University of Melbourne, and served in the AAMC in two world wars. Between the first and second wars he graduated in medicine and worked as a clinical assistant at the Alfred Hospital Asthma Clinic. During the second war he was appointed Lieut-Colonel, commanded the 2j3rd Casualty Clearing Station in the Western Desert and in New Guinea, was twice mentioned in despatches and was decorated. After a serious illness in 1945 he was discharged from the army in precarious health, specialized in Anaesthesia and became an Honorary Senior Anaesthetist at the Alfred and Heidelberg Hospitals, and a Fellow of the Royal Australasian College of Surgeons. Dr. Gillespie played an important role in the founding of the Faculty of Anaesthesia, for he served on its first Council. This Council rapidly applied itself to the attainment and maintenance of a very high standard of anaesthesiology in Australia and New Zealand. They were deeply interested therefore in education and founded the fellowship examinations of the Faculty. It is a pleasure to commemorate the work of so fine an anaesthetist who was also a brave, quiet retiring man, efficient courteous and friendly, able to inspire confidence in patients and calm efficient friendly team work in the operating theatre. This I do by attempting to give a lecture which is pre-eminently for those now studying for the primary examination of the Royal College of Surgeons Faculty of Anaesthetists, My assignment is to consider and classify factors responsible for drug interations. The classification proposed is shown in Table 1 .
l. PHARMACEUTICAL INTERACTIONS
Pharmaceutical interactions may occur when two drugs are mixed in a syringe or are added to infusion fluids prior to their administration. So many of these pharmaceutical inactivations and precipitations have been demonstrated that clinicians now adopt a working rule never to mix two drugs in this manner unless absence of interaction has received prior demonstration.
INTERFERENCE WITH ABSORPTION
The absorption of drug B by administration of drug A can produce both useful and deleterious interactions ( Table 2) . Anaesthetists frequently prolong the action and delay the absorption of non-constrictor local anaesthetics by addition of a vaso-constrictor such as adrenaline. Here the action is useful. Anaesthesia and Intensive Care, Vol. Ill, No. 1, February, 1975 c ;\L~RY LOCKETT Deleterious interactions by effect on absorption arise most commonly after the oral administration of both drugs. Proven drug interaction in the gastrointestinal tract has, so far, been found attributable to one of four different mechanisms. (i) Induction of change in the pH of the gastrointestinal contents by one drug is likely to effect the absorption of the other if the second drug is either weakly acidic or weakly basic. Under normal physiological conditions weak acids are absorbed from the stomach, provided their unionized molecules have adequate lipid solubility and weak bases, unionized in plasma diffuse into the gastric lumen, ionize and are trapped. The relative rates of transit of unionized molecules across the gastric mucosa is usually predictable from a knowledge of the pka of the drug, the lipid solubility of the unionized molecule, the concentration gradient, the pH gradient and the molecular size. The gastric mucosa behaves as a lipid barrier with an effective pH of 3·5 at the absorption barrier. A rise of pH in the gastric contents caused, for instance, by the administration of an antacid drug reduces the absorption of weak acids from, and the trapping of weak bases in, the lumen of the stomach.
Similar considerations apply to the passage of drugs across the intestinal mucosa where the effective pH in the membrane is approximately 5·5.
(ii) If drug B accelerates gastric emptying, transit of drug A through the gastric mucosa will be decreased. However, since absorption from the lumen of the intestine is commonly faster than from the lumen of the stomach, the plasma concentration-time curve from drug A will tend to rise more steeply.
When drug A is absorbed slowly from the intestines, e.g. the glycosides and adrenal corticoids, or is absorbed selectively over a short length of the gut, e.g. riboflavine, increase in the rate of the passage of gut contents caused by drug B is likely to hinder the absorption of Aand vice versa.
(iii) Binding or chelation. Chemical and physico-chemical interactions can occur between drugs in the lumen of the G.!. tract which result in inactivation, or changes the rate of absorption. Iron and tetracyclines form insoluble, nonabsorbable chelates. Caffeine produces a readily absorbed complex with ergotamine. Adsorbents (e.g. kaolin) and ionic binding agents reduce the absorption of many drugs.
(iv) Significant competition for active-transport systems in the G.!. tract has not yet been reported, as far as I know.
(v) Irritant action in the G.I. tract, causing increase in vascularity or frank ulceration necessarily influences drug absorption (KCI, salicylic acid). In the early stages of increased vascularity the absorption rates of many drugs are increased; in the later stages of fibrosis they are decreased. The prolonged use of irritant drugs can produce a mal-absorption syndrome. (Table 3 ) (i) One drug may change the volume of distribution of another by influencing fluid balance or fluid distribution. The administration of cardiac glycosides and bed rest may greatly reduce the extracellular fluid (E.C.F.) volume in patients suffering from congestive heart failure and, under such circumstances, will also improve the circulation of blood throughout the body. Improved absorption of drugs ad-
INTERACTION BY EFFECTS ON DISTRIBUTION

TABLE 3 Effects on Distribution
One drug may change the distribution of another by :
(1) Effects on fluid balance or fluid distribution (2) Effects on transport systems (3) Displacement from binding sites (a) Extracellular (b) Intracellular ministered orally or by injection therefore accompanies shrinkage of the volume of distribution, increasing the effective [drug concentration. If a powerful diuretic agent is also employed, shrinking of the E.C.F. is accelerated and effects of changes in electrolyte balance may complicate the picture.
(ii) One drug may influence the volume of distribution of another by action on transport systems, e.g. the well known expansion of the glucose and galactose space by insulin.
(iii) One drug may displace another from its binding state. This subject has received extensive study in the field of drug-binding to plasma proteins. The degree to which drug B displaces drug A from binding sites on plasma protein will be dependant on the relative affinities of A and B for the binding sites and the concentrations of the two drugs in the plasma water. Displacement of drug A by B is probably of clinical significance only when:
(a) A is over 90 per cent bound to plasma protein. When these three criteria are fulfilled, drug interactions of this type can be of really serious clinical consequence--e.g. displacement of warfarin from its protein binding by phenylbutazone. Table 4 lists acidic drugs which are over 90 per cent bound in plasma to plasma proteins. When the patient is receiving normal therapeutic doses, these drugs compete for common binding sites on plasma albumen molecules. All these drugs are therefore capable of interacting in the plasma. All are distributed into the volume of the E.C.F. Basic drugs also bind to plasma proteins and are capable of displacing one another from binding sites. However, those drugs which are bound have, so far, had very large volumes of distribution-hence the proportion of the total drug in the body bound to plasma protein is small, and, when released, it distributes throughout a large volume. Hence dangerous interactions of this type should not occur.
Probably, similar displacements of drug A by drug B occur at binding sites within cells. The resultant concentrations of A within the cytoplasm could, theoretically, be fatal to cells when A is extensively bound. This possibility may eventually account for some of the unexplained cases of renal tubular and hepatic necrosis. (Table 5 ) Drug interactions at receptor sites have received intensive and fruitful study.
RECEPTOR SITE INTERACTIONS
(i) Competitive and non-competitive antagonism of cholinergic neurones occurs at parasympathetic peripheral receptors and at the neuromuscular junction in voluntary muscle.
(ii) Action on transport systems. The potentiation of the actions of noradrenaline by cocaine is in large part due to prevention of the re-uptake of noradrenaline into the nerve terminal by cocaine.
Guanethidine and bethanidine are taken up into sympathetic nerve endings by an active transport mechanism which can be blocked competitively by sympathomimetic amines, chlorpromazine, antiantihistamines (some) and tricyclic antidepressants. Therapeutic concentrations of these drugs thus antagonize the fall in mean arterial pressure normally caused by guanethide and bethanidine, and tricyclic depressants may potentiate pressor effects of adrenaline and noradrenaline.
(iii) The synthesis of noradrenaline can be antagonized in sympathetic neurones by high doses of chlorpromazine or of guanethidine and a false transmitter L-methyl noradrenaline is formed from L methyl dopa. The latter competes with dopa in the synthesis of noradrenaline. All drugs which cause complete or partial chemical blockade to the local synthesis of transmitter produce some degree of denervation hypersensitivity in the receptors and therefore enhance the effects of injected exogenous transmitter.
(iv) Transmitter destruction, e.g. monoamine oxidase inhibitors.
(v) Changes in electrolyte balance can greatly effect a local drug action. Hypokalaemia induced by diuretics potentiates the effects of cardiac glycosides, prolongs the actions of Interactions at Receptor Sites 1. Competitive and non-competitive antagonism 2. Action on transport systems 3. Action on transmitter synthesis 4. Action on transmitter destruction 5. Production of change in receptor sensitivity (a) by local action (b) by influence on electrolyte and/or fluid balance non-depolarizing neuromuscular blocking drugs and antagonizes the antiarrhythmic actions of phenytoin, procainamide, lignocaine and quinidine.
Phenylbutazone and related pyrazolones induce salt and water retention and so reduce the anti-hypertensive effects of diuretics and other hypotensive drugs.
Interactions between drugs acting on the same
Physiological system Included under this heading are interactions between drugs acting within the central nervous system (CNS) that are as yet not understood.
Here numbers of inhibitory and excitatory dendrites impinge on single cells and release a variety of different chemical transmitters on one cell surface within which rhythmic, almost wavelike, slow changes occur in the level of cellular metabolism.
Some of these interactions are definitely at the receptor level, e.g. the antagonism of morphine by nalorphine. The manner in which the effects of hypnotics are potentiated by ethanol, narcotic analgesics, antihistamines and tranquillizers is not yet explained.
Outside the CNS, blockade of neural influence on the heart by administration of atropine together with a B-blocking agent can result in interaction with anaesthetic agents. Under these circumstances ethyl ether may depress cardiac output markedly. Anaesthetic agents not infrequently potentiate the actions of antihypertensive drugs, as do diuretics, ~ blockers, monoamine oxidase inhibitors and many of the C1\S depressants. (Table 6) :VIetabolic transformations of drugs are not confined to the liver. The liver microsomal enzyme system is however, far and away the major patlm·ay of drug metabolism. The major types of enzyme activity of the microsomal system are shown in Table 6 (column 2). This system curics out oxidations, rcductions and hydrolyses. This whole enzyme system operates as a unit and readily undergoes induction in response to substrate loads from food additives, mildly toxic components of the local diet, and from the use of drugs. A list of drugs known to cause enzyme induction in the microsomal enzyme system of the liver as a whole is shown in Table 7 . Animal experiments indicate that this list should be much longer. Induction begins about the fourth day of treatment and reaches the limit in about four weeks. If we prescribe an inducing drug whilst administering a non-inducing drug, which is metabolyzed by the liver microsomal system-the non-inducing drug will become more rapidly metabolized and the duration of its effect curtailed. There have been a number of tragedies resulting from stabilization of patients on warfarin in hospital where they are sometimes routinely given enzyme inducing hypnotics. On discharge from hospital they no longer need an hypnotic. It is stopped or they do not take it and regression of the microsomal svstem occurs in the course of three to four weeks. \Varfarin dosage is now too high, for vvarfarin is metabolized by the microsomal system-and the patient bleeds.
Drugs are also known to inhibit the microsomal system. In man, this certainly is the case with high doses of oestrogen; again, this list should almost certainly be longer. Anaesthesia and Intensive Care, Vol. Ill, No. 1, February, 1975 The function of the liver microsomal system is usually gravely impaired by any drug which is hepatotoxic.
Drug interactions also occur within this system as a result of substrate competition, interference with drug transport, and depletion of hepatic glycogen.
Drug metabolism does of course occur outside the microsomal system. Anaesthetists are for instance very well aware that hexafluorenium and propanidid prolong muscle paralysis induced by succinyl choline because they compete with succinyl choline for hydrolysis by the pseudocholinesterase of plasma.
INTERACTION OF DRUGS AND THEIR
METABOLITES DURING EXCRETION
Over 70 per cent of drug excretion takes place through the kidney.
(i) Effects of pH change in the urine. The renal clearance of weak organic bases with pka values of 7·5 to 10 is increased if the urine is made strongly acid and is decreased by making the urine alkaline. Conversely, the clearance of weak organic acids is higher in alkaline than 
